Research programme: therapeutic antibodies - HiFiBiO/Janssen Biotech

Drug Profile

Research programme: therapeutic antibodies - HiFiBiO/Janssen Biotech

Latest Information Update: 22 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator HiFiBiO; Janssen Biotech
  • Class Antibodies; Antineoplastics
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Autoimmune disorders; Cancer

Most Recent Events

  • 16 May 2018 Early research in Autoimmune disorders in USA (unspecified route), before May 2018
  • 11 Jun 2015 HiFiBiO and Janssen Biotech agree to co-develop therapeutic antibodies against a target antigen selected by Janssen Research & Development
  • 11 Jun 2015 Early research in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top